Trastuzumab--mechanism of action and use in clinical practice.
By C. Hudis. New England Journal of Medicine, 2007
2,521 citations recorded by the source corpus.
Subfields: Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/9cab0e408bddbc6d92788f0742492973f56225c5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Targeting the cancer kinome through polypharmacology (2010, neutral): “…that are more likely to respond to kinase inhibitor therapy — such as EGFR mutations in lung cancer 18 , ERBB2 overexpression in breast cancer 19 , and wild-type KRAS in lung and colorectal cancer 20,21 — but even among these sub-groups, relapse is inevitable for patients with disseminated…”
- Antibody therapy of cancer (2012, background): “The abrogation of tumour cell signalling (for example, by cetuximab and trastuzumab”
- Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “In addition to the small-molecule kinase inhibitors, kinase-targeted antibodies have also demonstrated efficacy in various cancers, for example, cetuximab in colorectal and head and neck cancer, and trastuzumab in breast cancer [26, 27].”
- Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, background): “The mechanisms of action by which trastuzumab exerts its antitumour effects include inhibition of receptor dimerization, endocytic destruction of the receptor and immune activatio”
- ErbB receptors and signaling pathways in cancer. (2009, background): “trastuzumab is used in combination with traditional chemotherapy and has had a significant impact on diseasefree survival of patients with early-stage ErbB2+ breast cancer [18].”
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008, background): “Although the mechanisms for response to trastuzumab are not completely understood, clinical benefit is attributed to interference with signal transduction pathways, impairment of extracellular domain (ECD) cleavage, inhibition of DNA repair, decreased angiogenesis; as well as induction of cell cycle”
- The epidermal growth factor receptor family: Biology driving targeted therapeutics (2008, background): “Trastuzumab is widely used in the treatment of ErbB2-amplified breast cancer where it causes tumor regression in 11 – 26 % of patients with metastatic disease and increases disease-free survival when used with traditional chemotherapy in early stage disease [163-165].”
- Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling (2011, background): “For this,wemadeuseof samples from twoseries of HER2-overexpressing patients with metastatic breast cancer treated at the Antoni van Leeuwenhoek Hospital (n = 34) and the M.D. Anderson Cancer Center (n = 21).”
- The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. (2009, background): “5 Yes Yes Not given Both HER-2 and EpCAM expression were independent predictors of OS 79 Kato et al. (2002) [89] 408 Paraffin IHC 30.5 Yes No RFS, 1.4; OS, 1.8 HER-2 status was an independent predictor in some, but not all, patient cohorts 80 el-Amady et al. (2002) [90] 94 Fresh ELISA 51 Yes Yes Not”
- Latent bone metastasis in breast cancer tied to Src-dependent survival signals (2009, background): “Despite effective systemic treatments, including chemotherapy, hormone therapy, and monoclonal antibody therapy, high-risk subsets of patients continue to have unacceptable rates of relapse in the bone and other organs (Hayes et al., 2007; Hudis, 2007).”